Skip to main content
Premium Trial:

Request an Annual Quote

Einstein Center Reaps $17M from NCI for Infrastructure, Research Support

NEW YORK (GenomeWeb News) – The Albert Einstein Cancer Center (AECC) at Yeshiva University has received a $16.7 million grant from the National Cancer Institute to provide for support and infrastructure of its research programs, which involve a range of molecular, genomics, imaging, and related disciplines.

The funding will bolster research projects in five major areas at AECC, including studies of the tumor microenvironment and metastasis; stem cells, differentiation and cancer; experimental therapeutics; cancer epidemiology; and the biology of colon cancer, AECC said yesterday.

Supporting these research programs are 14 specialized shared resource facilities involving genomics, proteomics, biostatistics and bioinformatics, structural biology, transgenic mouse resource, and others. The new funding also would provide for a new shared resource, a cancer biospecimen and acquisition biorepository.

AECC's genomics facility provides a range of sequencing services , including massively-parallel assays for expression, resequencing and de novo sequencing; gene expression, exon, and SNP arrays from Affymetrix; SNP typing, CpG methylation, and gene expression from Sequenom; real-time PCR using Sybr Green and Taqman assays; DNA purification; pyrosequencing, and others.

The proteomics core lab provides protein identification services; analysis of small proteins; spatial localization of molecules by mass spectrometry; quantitative proteomics; confirmation of synthetic and recombinant molecules, and multiple reaction monitoring assays and pharmacokinetics, among others.

AECC said its location in the Bronx, New York, provides its researchers with access to samples from and studies of diverse ethnic and racial populations, making it "a national resource."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.